What the FDA labels say about taking them together
Indomethacin and nabumetone
Indomethacin's FDA label of December 19, 2025 names nabumetone in its drug interactions section; nabumetone's label does not name indomethacin itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The indomethacin label: “Concomitant use of INDOCIN and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.”
Check it at the source: the indomethacin FDA label on DailyMed (effective December 19, 2025, Glenmark Pharmaceuticals Inc., USA); the nabumetone FDA label on DailyMed (effective January 13, 2025, ScieGen Pharmaceuticals Inc).
What does the indomethacin label say about nabumetone?
Indomethacin label, drug interactionsPemetrexed Clinical Impact: Concomitant use of indomethacin capsules and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
Source: FDA drug label (Indocin, NDA018332), Zyla Life Sciences US LLC, effective December 16, 2024 (SPL set 73878376-1d24-423b-9f37-3666e83c95da), via openFDA
Source: FDA drug label (Indomethacin), Glenmark Pharmaceuticals Inc., USA, effective December 19, 2025 (SPL set f7ed39e2-5431-4e47-935c-c7441d058f94), via openFDA; the full label on DailyMed
What does the nabumetone label say about indomethacin?
Nabumetone's label does not name indomethacin itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Nabumetone label, boxed warningNSAIDs 1 cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Nabumetone label, boxed warningCardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
Source: FDA drug label (Nabumetone), ScieGen Pharmaceuticals Inc, effective January 13, 2025 (SPL set 80c6888d-03b4-44f3-b94d-bcf5154ceae5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Indomethacin | Nabumetone | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Osteoarthritis | Osteoarthritis, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.210 per capsule 75 mg capsule | $0.128 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once